Bintrafusp alfa is currently undergoing phase III clinical evaluation as a first-line treatment in patients with advanced NSCLC with a high-level expression (≥50%) of PD-L1, using pembrolizumab as a comparator (NCT03631706) [157]. Here, CD274 is linked to non-small cell lung carcinoma.